

The effect of lower salt exposure on the cardiac structure and function of patients on home haemodialysis

ACTRN12611000975998

Status	RECRUITING
Phase	Phase 3
Sponsor	The Centre for Clinical Research and effective practice (CCRep), registered with the New Zealand Charities Commission (ref# CC21537)
Enrollment	118 participants

Plain Language Summary

This study (called the SOLID Trial) is testing whether reducing the amount of salt used during home dialysis can improve heart health in people with kidney failure. Dialysis patients have a very high risk of dying from heart disease, and researchers believe that simply lowering the salt content of dialysis fluid could help. This is a cost-free change that could save lives.

You may be eligible if:

- You are 18 years or older
- You are on home haemodialysis or self-care facility haemodialysis for kidney failure
- Your blood sodium level is normal or above normal
- Your kidney specialist agrees you are suitable for both low and standard salt dialysis

You may NOT be eligible if:

- You receive dialysis more than 3.5 times per week
- You are expected to live less than 12 months
- You are scheduled for a kidney transplant within the next 12 months
- You have a known serious heart muscle disease (such as amyloid or hypertrophic cardiomyopathy)
- You have severe aortic valve disease

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- Incident or prevalent patients treated with maintenance home haemodialysis or self care facility haemodialysis for end-stage kidney failure
- 2. Aged 18 years or older
- 3. Suitable for both low and standard dialysate [Na⁺] in the view of the treating physician
- 4. The person is willing to participate and has signed the Participant Information and Consent Form
- 5. Pre-dialysis plasma [Na⁺] > or = 135mM
- 6. The treating nephrologist agrees to the person's participation in the SOLID trial

Exclusion (8)

- Haemodialysis treatments at a frequency of greater than 3.5 times per week
- Treatment with maintenance haemodiafiltration
- Life expectancy of less than 12 months
- Scheduled for live donor kidney transplantation within 12 months of entry to the study
- Considered by the treating nephrologist to have concomitant illnesses or conditions that limit or contraindicate study procedures and followup (e.g. frequent intra-dialytic hypotension requiring fluid resuscitation)
- ... and 3 more (see full listing online)

Locations (1 total)

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12611000975998>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.

